Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease
نویسندگان
چکیده
منابع مشابه
Valganciclovir for symptomatic congenital cytomegalovirus disease.
BACKGROUND The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time. METHODS We conducted a randomized, placebo-controlled trial of valganciclovir therapy in neonates with symptomatic congenital CMV disease, comparing 6 months of therapy with 6 weeks...
متن کاملSymptomatic infant characteristics of congenital cytomegalovirus disease in Australia.
BACKGROUND Human cytomegalovirus (CMV) is the most common cause of viral intrauterine infection. In utero transmission can occur during primary maternal infection, reactivation or reinfection of seropositive mothers. OBJECTIVE To describe the aetiology and clinical features of infants diagnosed with congenital CMV and to document maternal factors that were presented. METHODS Active national...
متن کاملUltrasound prediction of symptomatic congenital cytomegalovirus infection.
OBJECTIVE The objective of the study was to assess the effectiveness of ultrasound in the antenatal prediction of symptomatic congenital cytomegalovirus (CMV) infection. STUDY DESIGN The sonograms of 650 fetuses from mothers with primary CMV infection were correlated to fetal or neonatal outcome. Infection status was disclosed by viral urine isolation at birth or CMV tissue inclusions at auto...
متن کاملPrognostic markers of symptomatic congenital cytomegalovirus infection.
The objective of this research was to identify maternal and fetal characteristics as prognostic markers of congenital cytomegalovirus (CMV) infection. This is a descriptive study of 13 cases of congenital CMV infection referred to Institute de Puericulture et Perinatologie de Paris (IPP) from January 2005 to October 2006. Amniotic fluid puncture was performed to research CMV polimerase chain re...
متن کاملValganciclovir: Dosing Strategies for Effective Cytomegalovirus Prevention
Valganciclovir has widely become the agent of choice for the prevention of cytomegalovirus in recipients of organ transplants. Optimal dosing is needed to achieve efficacy and avoid toxicity. For subjects at high risk of cytomegalovirus, it is strongly suggested that full-dose (based on renal function) valganciclovir be used. While low-dose valganciclovir appears to be efficacious in some repor...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: New England Journal of Medicine
سال: 2015
ISSN: 0028-4793,1533-4406
DOI: 10.1056/nejmoa1404599